News Sentiment

APRE sentiment intelligence

Aprea Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.75 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.5% over one week, +8.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial

Market Reaction

Balanced read

52/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 0.5% Price digesting
Trend fit Trend inactive 8.6% over four weeks
Fair value -74.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 33
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 7
TradingKey 7
Stock Titan 5
Moomoo 3
Finviz 2
simplywall.st 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 18
Analyst action 6
Guidance 2
Regulatory and legal 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-56 of 56
Stock Titan Direct company coverage

[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7)

Aprea Therapeutics, Inc. has filed a prospectus supplement (424B7) to register 5,503,556 shares of Common Stock for resale by selling stockholders, updating a previous prospectus from December 29, 2025. The filing details the composition of these shares, including those issued in

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 20:08
Source
Stock Titan
BioBuzz Direct company coverage

Greater Philadelphia-based Aprea Therapeutics Raises $30M to Extend Runway and Reposition Its Precision Oncology Bet

Aprea Therapeutics, based in Greater Philadelphia, has secured a $30 million private placement to advance its new lead program, APR-1051, a WEE1 kinase inhibitor for solid tumors. This funding aims to extend the company's cash runway into Q1 2028, allowing it to continue early cl

Tone
Positive 66/100
Event
Balance sheet
Published
14 May 2026 13:40
Source
BioBuzz
Moomoo Direct company coverage

Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating

Wedbush has revised its price target for Aprea Therapeutics to $6, down from the previous target of $7. Despite this reduction, the firm has decided to maintain its Outperform rating on the company's stock. This adjustment reflects a moderated outlook while still indicating confi

Tone
Negative 39/100
Event
Analyst action
Published
14 May 2026 10:39
Source
Moomoo
Zacks Investment Research Direct company coverage

Should I buy Aprea Therapeutics (APRE)

Tone
Positive 66/100
Event
Market update
Published
23 Aug 2016 06:53
Source
Zacks Investment Research